NCT05189860 (C-MIC-II-FU) is a NA clinical trial of C-MIC system in Systolic Left Ventricular Dysfunction, sponsored by Berlin Heals GmbH.

Who is sponsoring NCT05189860?

NCT05189860 is sponsored by Berlin Heals GmbH.

What drugs are being tested in NCT05189860?

Interventions in NCT05189860: C-MIC system.

What condition does NCT05189860 study?

NCT05189860 studies Systolic Left Ventricular Dysfunction.

Is NCT05189860 still recruiting?

NCT05189860 is currently recruiting now. Last updated 8 June 2025.

Last reviewed 2025-06-08 · How we verify

NCT05189860: C-MIC-II-FU

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The C-MIC-II Follow-Up Study

Recruiting now NA Last updated 8 June 2025

What this trial tests

NA trial testing C-MIC system in Systolic Left Ventricular Dysfunction in 31 participants. Currently enrolling.

Timeline

3 March 2022

Primary endpoint
15 November 2026

15 November 2026

Quick facts

Lead sponsor	Berlin Heals GmbH
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	31
Start date	3 March 2022
Primary completion	15 November 2026
Estimated completion	15 November 2026
Sites	6 locations across Serbia, Bosnia and Herzegovina, Croatia, North Macedonia

Drugs / interventions tested

C-MIC system

Conditions studied

Systolic Left Ventricular Dysfunction — all drugs for Systolic Left Ventricular Dysfunction →

Sponsor

Berlin Heals GmbH — full company profile →

Who can join

Adults 18 to 75, any sex, with Systolic Left Ventricular Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The C-MIC System is a medical device used to treat heart failure per the intended purpose which is to treat heart failure by applying an electrical micro-current to the heart. Target patients for this study are patients who have received the device in a prior study.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Cardio-microcurrent device treatment for heart failure with reduced ejection fraction: Results from the C-MIC II open-label randomized controlled trial.
Rame JE, Schmitto JD, Kosevic DN, Kovacevic-Preradovic T, et al · · 2025 · cited 3× · PMID 40660878 · DOI 10.1002/ejhf.3763
Two-year outcomes of a cardiac microcurrent device in chronic heart failure: A first-in-human pilot study.
Kosevic DB, Radak U, Vukovic P, Schmitto JD, et al · · 2025 · cited 3× · PMID 40634236 · DOI 10.1002/ehf2.15369

Verify or expand the search:

Other Berlin Heals GmbH trials

Trials by the same sponsor.

NCT04662034 — Performance and Safety of the Cardiac Microcurrent Therapy System · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05189860 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Berlin Heals GmbH
Last refreshed: 8 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05189860.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing